Innovative Drug Rezpegaldesleukin to be Featured at AAD Annual Meeting 2026
The upcoming American Academy of Dermatology (AAD) Annual Meeting 2026 is poised to spotlight revolutionary treatments for chronic skin conditions, particularly those targeting autoimmune disorders. Nektar Therapeutics, a clinical-stage biotechnology company based in San Francisco, has announced that its innovative drug, Rezpegaldesleukin, will be presented during the event, which takes place from March 27-31, 2026, in Denver, Colorado.
Rezpegaldesleukin is a first-in-class regulatory T cell stimulator. It addresses the underlying issues of immune imbalance that contribute to autoimmune diseases and chronic inflammatory conditions. By specifically targeting the IL-2 receptor complex, this therapeutic agent stimulates the proliferation of regulatory T cells (Treg) while avoiding activation of cytotoxic CD8+ and CD4+ T cells, which are known to exacerbate autoimmune disorders. This mechanism establishes a new approach to restoring immune balance.
Nektar Therapeutics will present data from two Phase 2b clinical trials focusing on atopic dermatitis and alopecia areata:
1. Late-Breaking Research Oral Presentation (Abstract 79863)
- Title: "Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin Phase 2b Efficacy and Safety Results Following 36-Weeks of Therapy in Severe-to-Very-Severe Alopecia Areata"
- Presenter: David Rosmarin, MD, FAAD
- Date/Time: Saturday, March 28, 2026, from 10:36 to 10:48 AM MST
- Location: Colorado Convention Center, Bellco Theatre 3
2. ePoster Oral Presentation (Abstract 73858)
- Title: "Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis"
- Presenter: Raj Chovatiya, MD, PhD, MSCI, FAAD
- Date/Time: Saturday, March 28, 2026, from 11:40 to 11:45 AM MST
- Location: Colorado Convention Center, Lobby C, Poster Center 1
The REZOLVE-AA study focuses on patients with severe-to-very-severe alopecia areata who have not been treated previously with JAK inhibitors or other biologic therapies. The study was completed in February 2025 and included approximately 30 global sites, with significant patient recruitment from Poland, Canada, and the United States. The primary endpoint measures the reduction in the Severity of Alopecia Tool (SALT) score at Week 36.
On the other hand, the REZOLVE-AD study conducted a Phase 2b trial with 393 patients suffering from moderate to severe atopic dermatitis. Patients were randomized into various dosing regimens to ascertain the drug's efficacy in reducing Eczema Area and Severity Index (EASI) scores after a period of treatment. This trial is crucial as it explores the treatment's long-term impact while emphasizing re-randomization based on patient responsiveness.
The necessity for insights from these studies is underscored by the FDA’s Fast Track designations in both cases for individuals aged 12 and older. For atopic dermatitis, Fast Track status was awarded in February 2025. The same designation was granted for alopecia areata in July 2025. These designations expedite the development and review processes for drugs that fulfill unmet medical needs.
Nektar promotes Rezpegaldesleukin as a highly promising therapeutic option due to its unique action in regulating immune responses. The company’s commitment to developing new treatments for chronic inflammatory diseases exemplifies its innovation in biotechnology.
The presentations at the AAD Annual Meeting 2026 will represent significant advancements in the treatment landscape for autoimmune conditions. They signify a collective push towards understanding and developing effective therapies that address not only symptoms but also the core causes of autoimmune disorders, thereby enhancing patient quality of life. Nektar Therapeutics' efforts with Rezpegaldesleukin are setting the stage for what could become a groundbreaking paradigm in treating these challenging conditions. Those interested in the latest advancements in dermatological treatments should mark their calendars for these highly anticipated presentations.
For further information, visit Nektar Therapeutics' official website at www.nektar.com.
An Overview of Rezpegaldesleukin
Rezpegaldesleukin is a first-in-class regulatory T cell stimulator. It addresses the underlying issues of immune imbalance that contribute to autoimmune diseases and chronic inflammatory conditions. By specifically targeting the IL-2 receptor complex, this therapeutic agent stimulates the proliferation of regulatory T cells (Treg) while avoiding activation of cytotoxic CD8+ and CD4+ T cells, which are known to exacerbate autoimmune disorders. This mechanism establishes a new approach to restoring immune balance.
Presentation Highlights
Nektar Therapeutics will present data from two Phase 2b clinical trials focusing on atopic dermatitis and alopecia areata:
1. Late-Breaking Research Oral Presentation (Abstract 79863)
- Title: "Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin Phase 2b Efficacy and Safety Results Following 36-Weeks of Therapy in Severe-to-Very-Severe Alopecia Areata"
- Presenter: David Rosmarin, MD, FAAD
- Date/Time: Saturday, March 28, 2026, from 10:36 to 10:48 AM MST
- Location: Colorado Convention Center, Bellco Theatre 3
2. ePoster Oral Presentation (Abstract 73858)
- Title: "Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis"
- Presenter: Raj Chovatiya, MD, PhD, MSCI, FAAD
- Date/Time: Saturday, March 28, 2026, from 11:40 to 11:45 AM MST
- Location: Colorado Convention Center, Lobby C, Poster Center 1
The Research—REZOLVE-AD and REZOLVE-AA Studies
The REZOLVE-AA study focuses on patients with severe-to-very-severe alopecia areata who have not been treated previously with JAK inhibitors or other biologic therapies. The study was completed in February 2025 and included approximately 30 global sites, with significant patient recruitment from Poland, Canada, and the United States. The primary endpoint measures the reduction in the Severity of Alopecia Tool (SALT) score at Week 36.
On the other hand, the REZOLVE-AD study conducted a Phase 2b trial with 393 patients suffering from moderate to severe atopic dermatitis. Patients were randomized into various dosing regimens to ascertain the drug's efficacy in reducing Eczema Area and Severity Index (EASI) scores after a period of treatment. This trial is crucial as it explores the treatment's long-term impact while emphasizing re-randomization based on patient responsiveness.
The Potential of Rezpegaldesleukin
The necessity for insights from these studies is underscored by the FDA’s Fast Track designations in both cases for individuals aged 12 and older. For atopic dermatitis, Fast Track status was awarded in February 2025. The same designation was granted for alopecia areata in July 2025. These designations expedite the development and review processes for drugs that fulfill unmet medical needs.
Nektar promotes Rezpegaldesleukin as a highly promising therapeutic option due to its unique action in regulating immune responses. The company’s commitment to developing new treatments for chronic inflammatory diseases exemplifies its innovation in biotechnology.
Conclusion
The presentations at the AAD Annual Meeting 2026 will represent significant advancements in the treatment landscape for autoimmune conditions. They signify a collective push towards understanding and developing effective therapies that address not only symptoms but also the core causes of autoimmune disorders, thereby enhancing patient quality of life. Nektar Therapeutics' efforts with Rezpegaldesleukin are setting the stage for what could become a groundbreaking paradigm in treating these challenging conditions. Those interested in the latest advancements in dermatological treatments should mark their calendars for these highly anticipated presentations.
For further information, visit Nektar Therapeutics' official website at www.nektar.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.